GAMMA Investing LLC Increases Stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

GAMMA Investing LLC grew its holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 763.3% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 42,190 shares of the medical device company's stock after buying an additional 37,303 shares during the quarter. GAMMA Investing LLC owned 0.06% of Tandem Diabetes Care worth $808,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in shares of Tandem Diabetes Care by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 7,440,005 shares of the medical device company's stock valued at $267,989,000 after purchasing an additional 77,451 shares during the last quarter. ArrowMark Colorado Holdings LLC lifted its position in Tandem Diabetes Care by 14.1% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 2,723,715 shares of the medical device company's stock worth $98,108,000 after acquiring an additional 337,026 shares during the period. GW&K Investment Management LLC lifted its holdings in shares of Tandem Diabetes Care by 18.0% in the 4th quarter. GW&K Investment Management LLC now owns 2,123,488 shares of the medical device company's stock valued at $76,488,000 after buying an additional 323,674 shares during the period. Jacobs Levy Equity Management Inc. increased its stake in Tandem Diabetes Care by 189.0% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,661,013 shares of the medical device company's stock valued at $59,830,000 after purchasing an additional 1,086,337 shares in the last quarter. Finally, Park West Asset Management LLC increased its position in Tandem Diabetes Care by 49.5% during the fourth quarter. Park West Asset Management LLC now owns 1,600,000 shares of the medical device company's stock worth $57,632,000 after buying an additional 530,000 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on TNDM. Truist Financial assumed coverage on Tandem Diabetes Care in a report on Monday. They issued a "hold" rating and a $24.00 target price on the stock. Sanford C. Bernstein downgraded Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and cut their target price for the stock from $35.00 to $25.00 in a research report on Friday, February 28th. Stifel Nicolaus cut their target price on shares of Tandem Diabetes Care from $60.00 to $31.00 and set a "buy" rating on the stock in a research note on Thursday, May 1st. Wall Street Zen raised shares of Tandem Diabetes Care from a "sell" rating to a "hold" rating in a research note on Friday, June 6th. Finally, Canaccord Genuity Group upped their price target on shares of Tandem Diabetes Care from $58.00 to $59.00 and gave the company a "buy" rating in a report on Thursday, May 1st. Ten equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Tandem Diabetes Care has an average rating of "Hold" and an average target price of $33.43.

Tandem Diabetes Care Stock Performance

NASDAQ TNDM opened at $20.07 on Wednesday. The firm has a market cap of $1.34 billion, a price-to-earnings ratio of -7.22 and a beta of 1.52. The company has a current ratio of 2.30, a quick ratio of 1.81 and a debt-to-equity ratio of 1.99. The company has a 50 day moving average of $20.06 and a 200-day moving average of $26.35. Tandem Diabetes Care, Inc. has a 1-year low of $15.75 and a 1-year high of $48.24.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.07). Tandem Diabetes Care had a negative net margin of 18.71% and a negative return on equity of 57.33%. The firm had revenue of $234.42 million during the quarter, compared to analyst estimates of $220.19 million. During the same period last year, the firm earned ($0.65) EPS. Tandem Diabetes Care's quarterly revenue was up 22.3% on a year-over-year basis. On average, equities analysts forecast that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current fiscal year.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.